Salmonella vaccine is an effective management tool to help control disease.
MADISON, N.J. — Dec. 22, 2010 — Pfizer Animal Health announces the availability of Salmonella Newport Bacterial Extract vaccine* with SRP® Technology, an effective management tool in the control of salmonellosis caused by Salmonella Newport. The Salmonella Newport Bacterial Extract vaccine with SRP Technology effectively controls infection and fecal shedding of Salmonella Newport, resulting in reduced disease incidence and improved herd performance.1
“The SRP Technology in the conditionally licensed Salmonella Newport Bacterial Extract vaccine uses the iron-gathering mechanism common to all Salmonella serotypes to control Salmonella Newport infection in vaccinated cattle,” says Gary Neubauer, DVM, senior manager, dairy veterinary operations, Pfizer Animal Health. “Antibodies generated by vaccination with the Salmonella Newport Bacterial Extract vaccine have been shown to recognize the siderphore receptors and porins (SRPs) of several common Salmonella serotypes.2”
Salmonella Newport Bacterial Extract vaccine with SRP Technology is an effective management tool to help control disease. Milk production and herd performance of cattle subclinically infected with Salmonella Newport can be improved through greater control of salmonellosis in vaccinated herds. A published study conducted in a dairy herd with no clinical signs of salmonellosis demonstrated that vaccination using the Salmonella Newport Bacterial Extract vaccine with SRP Technology resulted in 2.5 pounds more milk per cow per day in vaccinated cattle. There also was a reduction in somatic cell count associated with vaccination.1
Salmonellosis is an economically devastating disease to the dairy industry, and incidence is on the rise. According to the 2007 National Animal Health Monitoring Service report from the U.S. Department of Agriculture, 48 percent of all dairies were infected with Salmonella.3 The percentage of operations infected with Salmonella was nearly twice that of 1996, and over that same 10-year time period, the percentage of cows infected with Salmonella has more than doubled to 13.7 percent.
“Salmonellosis is a pervasive pathogen that is hard to keep out of a dairy operation,” Neubauer says. “Producers should work closely with their veterinarian to implement a Salmonella control program. All stakeholders in the food chain should work together to solve the Salmonella problem.”
Salmonella Newport Bacterial Extract vaccine with SRP Technology is manufactured by Epitopix LLC. Pfizer Animal Health acquired global rights to the vaccine earlier this year and will become the exclusive distributor beginning in 2011.
For more information, producers should contact their Pfizer Animal Health representative or their veterinarian.
About Pfizer Animal Health
Pfizer Animal Health, a business of Pfizer Inc., is a world leader in discovering and developing innovative animal vaccines and prescription medicines, investing an estimated $300 million annually in animal health product research and development. For more information about how Pfizer Animal Health works to ensure a safe, sustainable global food supply from healthy livestock, fish and poultry; or helps companion animals and horses to live longer, healthier lives, visit www.PfizerAH.com.
* The product license is conditional. Efficacy and potency studies in progress.
1 Hermesch DR, Thomson DU, Loneragan GH, Renter DR, White BJ. Effects of a commercially available vaccine against Salmonella enterica serotype Newport on milk production, somatic cell count and shedding of Salmonella organisms in female dairy cattle with no clinical signs of salmonellosis. AJVR 2008;69(9):1229-1234.
2 Epitopix, LLC. N-0005-136-142
3 National Animal Health Monitoring System. APHIS Info Sheet, Salmonella and Campylobacter on U.S. Dairy Operations, 1996–2007. July 2009, #N562.0709.